Literature DB >> 21153775

Prospective study of combination therapy with low-dose thalidomide plus prednisolone ameliorating cytopenia in primary myelofibrosis.

Yutaka Hattori, Yoshitaka Miyakawa, Kenji Yokoyama, Taketo Yamada, Wenlin Du, Masahiro Jinzaki, Hiroshi Shinmoto, Shinichiro Okamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21153775     DOI： 10.1007/s12185-010-0733-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  10 in total

1.  Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.

Authors:  G Barosi; A Grossi; B Comotti; P Musto; G Gamba; M Marchetti
Journal:  Br J Haematol       Date:  2001-07       Impact factor: 6.998

2.  Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.

Authors:  Jean-François Abgrall; Isabelle Guibaud; Jean-Noël Bastie; Michel Flesch; Jean-François Rossi; Laurence Lacotte-Thierry; Françoise Boyer; Philippe Casassus; Borhane Slama; Christian Berthou; Philippe Rodon; Michel Leporrier; Bruno Villemagne; Chantal Himberlin; Kamel Ghomari; Fabrice Larosa; Florence Rollot; Jacqueline Dugay; Christian Allard; Michel Maigre; Françoise Isnard; Robert Zerbib; Jean-Michel Cauvin
Journal:  Haematologica       Date:  2006-08       Impact factor: 9.941

3.  Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Authors:  Ayalew Tefferi; Jorge Cortes; Srdan Verstovsek; Ruben A Mesa; Deborah Thomas; Terra L Lasho; William J Hogan; Mark R Litzow; Jacob B Allred; Dan Jones; Catriona Byrne; Jerome B Zeldis; Rhett P Ketterling; Rebecca F McClure; Francis Giles; Hagop M Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

4.  Thalidomide therapy for myelofibrosis with myeloid metaplasia.

Authors:  Deborah A Thomas; Francis J Giles; Maher Albitar; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; Susan M O'Brien; Guillermo Garcia-Manero; Michael J Keating; Sherry Pierce; Jerome Zeldis; Hagop M Kantarjian
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

5.  Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.

Authors:  P P Piccaluga; G Visani; S A Pileri; S Ascani; T Grafone; A Isidori; M Malagola; C Finelli; G Martinelli; P Ricci; M Baccarani; S Tura
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

6.  Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

Authors:  Ayalew Tefferi; Srdan Verstovsek; Giovanni Barosi; Francesco Passamonti; Gail J Roboz; Heinz Gisslinger; Ronald L Paquette; Francisco Cervantes; Candido E Rivera; H Joachim Deeg; Juergen Thiele; Hans M Kvasnicka; James W Vardiman; Yanming Zhang; B Nebiyou Bekele; Ruben A Mesa; Robert P Gale; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

7.  Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

Authors:  Monia Marchetti; Giovanni Barosi; Francesca Balestri; Gianluca Viarengo; Sara Gentili; Sara Barulli; Jean-Loup Demory; Fiorella Ilariucci; Antonio Volpe; Dominique Bordessoule; Alberto Grossi; Marie Caroline Le Bousse-Kerdiles; Andrea Caenazzo; Alessandro Pecci; Antonietta Falcone; Giorgio Broccia; Cesarina Bendotti; Fredric Bauduer; Francesco Buccisano; Brigitte Dupriez
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

8.  A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Authors:  Ruben A Mesa; David P Steensma; Animesh Pardanani; Chin-Yang Li; Michelle Elliott; Scott H Kaufmann; Gregory Wiseman; Leigh A Gray; Georgene Schroeder; Terra Reeder; Jerome B Zeldis; Ayalew Tefferi
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

9.  Thalidomide for the treatment of idiopathic myelofibrosis.

Authors:  C Strupp; U Germing; A Scherer; A Kündgen; U Mödder; N Gattermann; R Haas
Journal:  Eur J Haematol       Date:  2004-01       Impact factor: 2.997

10.  Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

Authors:  Alfonso Quintás-Cardama; Hagop M Kantarjian; Taghi Manshouri; Deborah Thomas; Jorge Cortes; Farhad Ravandi; Guillermo Garcia-Manero; Alessandra Ferrajoli; Carlos Bueso-Ramos; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.